Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
50 Studies Every Urologist Should Know

50 Studies Every Urologist Should Know

9780190655341
280.73 zł
252.66 zł Save 28.07 zł Tax included
Lowest price within 30 days before promotion: 252.66 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
50 Studies Every Urologist Should Know presents key studies that have shaped the practice of urology. Selected using a rigorous methodology, the studies cover topics including reflux disease in paediatric urology, management of male erectile dysfunction and lower urinary tract symptoms, female urology and stone disease, the various forms of genitourinary cancer, and more. For each study, a concise summary is presented with an emphasis on the results and limitations of thestudy, and its implications for practice. An illustrative clinical case concludes each review, followed by brief information on other relevant studies. This book is a must-read for healthcare professionals in urology, as well as anyone who wants to learn more about the data behind clinicalpractice.
Product Details
OUP USA
90172
9780190655341
9780190655341

Data sheet

Publication date
2021
Issue number
1
Cover
paperback
Pages count
320
Dimensions (mm)
156 x 235
Weight (g)
450
  • Chapter 1: Radical prostatectomy versus observation for localized prostate cancer: The European Randomized Study of Screening for Prostate Cancer (ERSPC); Chapter 2: The Influence of Finasteride on the Development of Prostate Cancer: Prostate Cancer Prevention Trial (PCPT)1; Chapter 3: MRI-Targeted or Standard Biopsy for Prostate Cancer Diagnosis: The PRECISION Trial; Chapter 4: Long-term survival among men with conservatively treated localized prostate cancer: Conservative management of prostate cancer-watchful waiting; Chapter 5: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer; Chapter 6: Radical prostatectomy versus Observation in Early Prostate Cancer: Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4); Chapter 7: Radical prostatectomy versus observation for localized prostate cancer: The PIVOT Trial; Chapter 8: 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy: The Prostate Testing for Cancer and Treatment (ProtecT) trial; Chapter 9: Comparative Effectiveness of Minimally Invasive vs Open Radical Prostatectomy; Chapter 10: Quality of life and satisfaction with outcome among prostate-cancer survivors: Quality of life after primary treatment of localized prostate cancer; Chapter 11: Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial: The Southwest Oncology Group 8794 Trial; Chapter 12: Survival Following Primary Androgen Deprivation Therapy Among Men with Localized Prostate Cancer; Chapter 13: Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer; Chapter 14: Intermittent versus Continuous Androgen Deprivation in Prostate Cancer: Intermittent androgen deprivation therapy (SWOG Trial 9346); Chapter 15: Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer: The TAX 327 Trial; Chapter 16: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer; Chapter 17: Abiraterone and Increased Survival in Metastatic Prostate Cancer; Chapter 18: Enzalutamide in Metastatic Prostate Cancer before Chemotherapy: The PREVAIL Study; Chapter 19: The EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma; Chapter 20: Nephrectomy Followed by Interferon Alfa-2b Compared With Interferon Alfa-2b Alone For Metastatic Renal-Cell Cancer; Chapter 21: Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma; Chapter 22: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma: CheckMate 025; Chapter 23: The Effect of Intravesical Mitomycin C on Recurrence of Newly Diagnosed Superficial Bladder Cancer: A Further Report with 7 Years of Follow-Up; Chapter 24: Bacillus Calmette-Guerin (BCG) Immunotherapy for Recurrent Non-Invasive Transitional Cell Carcinoma of the Bladder: A Randomized Southwest Oncology Group Study; Chapter 25: Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer; Chapter 26: Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer; Chapter 27: A Randomized Comparison of Cisplatin Alone or in Combination with Methotrexate, Vinblastine, and Doxorubicin in Patients with Metastatic Urothelial Carcinoma: A Cooperative Group Study; Chapter 28: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study; Chapter 29: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma: KEYNOTE-045; Chapter 30: Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer; Chapter 31: Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide: PVB versus BEP; Chapter 32: Urinary Volume, Water and Stones Recurrence in Idiopathic Calcium Nephrolithiasis: a 5-Year Randomized Prospective Study; Chapter 33: A Prospective Study of Dietary Calcium and Other Nutrients and the Risk of Symptomatic Kidney Stones; Chapter 34: First Clinical Experience with Extracorporeally Induced Destruction of Kidney Stones by Shock Waves; Chapter 35: Shockwave lithotripsy versus ureteroscopy for lower pole caliceal calculi 1 cm or less; Chapter 36: Extracorporeal shockwave lithotripsy versus percutaneous nephrolithotomy for lower pole nephrolithiasis: The Lower Pole I Study; Chapter 37: Medical Expulsive Therapy in Adults with Ureteric Colic: The SUSPEND Trial; Chapter 38: Burch Colposuspension versus Fascial Sling to Reduce Urinary Stress Incontinence: The Stress Incontinence Surgical Treatment Efficacy (SISTEr) Trial; Chapter 39: Retropubic versus Transobturator Midurethral Slings for Stress Incontinence: The Trial of Mid Urethral Slings (TOMUS); Chapter 40: A midurethral sling to reduce incontinence after vaginal prolapse repair: The Outcomes Following Vaginal Prolapse Repair and Midurethral Sling (OPUS) trial; Chapter 41: A Randomized Trial of Urodynamic Testing Before Stress Incontinence Surgery: The VALUE Study; Chapter 42: Anticholinergic Therapy versus Onabotulinumtoxin A for Urgency Urinary Incontinence: The Anticholinergic versus Botulinum Toxin Comparison-ABC-study; Chapter 43: Oral sildenafil in the treatment of erectile dysfunction; Chapter 44: Treatment of men with erectile dysfunction with transurethral alprostadil; Chapter 45: Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux: Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial; Chapter 46: A Comparison of Transurethral Surgery with Watchful Waiting for Moderate Symptoms of Benign Prostatic Hyperplasia: The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate; Chapter 47: The Efficacy of Terazosin, Finasteride, or both in Benign Prostatic Hyperplasia: The Veterans Affairs Cooperative Benign Prostatic Hyperplasia Study; Chapter 48: Chlorhexidine-Alcohol versus Povidone- Iodine for Surgical-Site Antisepsis; Chapter 49: Clean, Intermittent Self-Catheterization in the Treatment of Urinary Tract Disease; Chapter 50: The Surgical Learning Curve for Prostate Cancer Control after Radical Prostatectomy;
Comments (0)

  • Frequently purchased together

    No products available